Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: A case series

World Journal of Biological Psychiatry

Volumn 13, Issue 1, 2012, Pages 14-21

  Higuma, Haruka ^a   Kanehisa, Masayuki ^a   Maruyama, Yoshihiro ^a   Ishitobi, Yoshinobu ^a   Tanaka, Yoshihiro ^a   Tsuru, Jusen ^a   Hanada, Hiroaki ^a   Kodama, Kensuke ^a   Isogawa, Koichi ^a   Akiyoshi, Jotaro ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Aripiprazole; Augmentation; Obsessivecompulsive disorder; SSRI

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; BIPERIDEN; BROMAZEPAM; CLOMIPRAMINE; FLUVOXAMINE; PAROXETINE; RISPERIDONE; SERTRALINE;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; FEMALE; GAF SCALE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGICAL RATING SCALE; Y BOCS SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863400374     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.551667     Document Type: Article

References (48)

1. AssiéMB, Ravailhe V, Faucillon V, Newman-Tancredi A. 2005. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profi le of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315:265-272. (Pubitemid 41380520)
2. Atmaca M, Kuloglu M, Tezcan E, Gecici O. 2002. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: A single-blind, placebo-controlled study. Int Clin Psychopharmacol 17:115-119. (Pubitemid 34442192)
3. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. 2006. A systematic review: antipsy-chotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622-632. (Pubitemid 43989810)
4. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, et al. 2005. Intrinsic effi cacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identifi cation of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278-1287. (Pubitemid 41635416)
5. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. 2004. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. J Clin Psychiatry 65:565-568.
6. Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. 2005. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebocontrolled study. BMC Psychiatry 5:5.
7. Chappell PB, Leckman JF, Riddle MA, Anderson GM, Listwack SJ, Ort SI, et al. 1992. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv Neurol 58:253-262.
8. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. 2005. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66: 49-51.
9. Denys D, de Geus F, van Megen HJ, Westenberg HG. 2004. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65: 1040-1048.
10. Endicott J, Spitzer RL, Fleiss JL, Cohen J. 1976. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766-771.
11. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. 2005. Low-dose risperidone augmentation of fl uvoxamine treatment in obsessivecompulsive disorder: A double-blind, placebo-controlled study. Eur Neuropsychopharmacol 15: 69-74. (Pubitemid 39574401)
12. Fineberg NA, Gale TM. 2005. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8:107-129. (Pubitemid 40388819)
13. Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, et al. 2006. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 21:337-343. (Pubitemid 44498275)
14. First MB, Spitzer RL, Gibbon M, Williams JB. 1996. Structured Clinical Interview for the DSM-IV Axis I Disorders. Washington: American Psychiatric Press.
15. Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P. 2008. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Ann Gen Psychiatry 23:26.
16. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. 1989. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011. (Pubitemid 19278229)
17. Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W. 2008. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 22:95.
18. Hollander E, Kaplan A, Allen A, Cartwright C. 2000. Pharmaco-therapy for obsessive-compulsive disorder. Psychiatr Clin North Am 23:643-656.
19. Insel TR, Pickar D. 1983. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry 140:1219-1220. (Pubitemid 13050743)
20. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. 1985. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 20:1174-1188. (Pubitemid 16053592)
21. Jefferys D, Burrows G. 2008. Reversal of trichotillomania with aripiprazole. Depress Anxiety 25:E37-40.
22. Kane J, Ingenito G, Ali M. 2000. Effi cacy of Aripiprazole in psychotic disorder: comparison with haloperidol and placebo. Schizophr Res 41:39.
23. Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. 1996. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 40:154-156. (Pubitemid 26202448)
24. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. 1999. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627. (Pubitemid 29189265)
25. Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, et al. 2010. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. Affect Disord 121(1-2):175-179.
26. Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T, et al. 2006. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112:126-133. (Pubitemid 44344618)
27. Matsunaga H, Hayashida K, Kiriike N, Maebayashi K, Stein DJ. 2009a. The clinical utility of symptom dimensions in obsessive-compulsive disorder. Psychiatry Res 180:25-29.
28. Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. 2009b. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 70: 863-868.
29. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. 1994. Haloperidol addition in fl uvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308. (Pubitemid 24127303)
30. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. 2000. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801. (Pubitemid 30650116)
31. Moran-Gates T, Massari C, Graulich A, Li égeois JF, Tarazi FI. 2006. Long-term effects of JL 13, a potential atypical antipsy-chotic, on rat dopamine and serotonin receptor subtypes. J Neurosci Res 84:675-682. (Pubitemid 44196708)
32. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. 2002. International Treatment Refractory OCD Consortium, Treatment non-response in OCD: methodological issues and operational defi nitions. Int J Neuropsy-chopharmacol 5:181-191. (Pubitemid 34669829)
33. Pessina E, Albert U, Bogetto F, Maina G. 2009. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 24: 265-269.
34. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. 1998. Acute and long-term effi cacy and safety of aripiprazole: A new atypical antipsychotic. Schizophr Res 29:155.
35. Saha AR, Petrie JL, Ali M W. 1999. Safety and effi cacy profi le of Aripiprazole, a novel antipsychotic. Schizophr Res 36:295.
36. Sandyk R. 1987. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int J Neurosci 35:93-94.
37. Sarkar R, Klein J, Krüger S. 2008. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychop-harmacology (Berlin) 197:687-688.
38. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. 2004. A double-blind, placebo controlled trial of olanzapine addition in fl uoxetine-refrac-tory obsessive compulsive disorder. Biol Psychiatry 55: 553-555.
39. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. 2003. Aripiprazole, a novel atypical anti-psychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411. (Pubitemid 41070874)
40. Singh JB, Zarate CA Jr. 2006. Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials. Bipolar Disord 8:696-709. (Pubitemid 44824710)
41. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, et al. 2007. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electro-physiolo gical studies. Psychopharmacology (Berlin) 190: 373-382. (Pubitemid 46155646)
42. Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. 2008. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 25:172-174. (Pubitemid 351341964)
43. Stringfellow J, Ingenito G, Marder SR. 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681-690. (Pubitemid 36818630)
44. Tarazi FI, Zhang K, Baldessarini RJ. 2002. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berlin) 161:263-270. (Pubitemid 34591664)
45. Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M. 2002. Tandospirone potentiates the fl uoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem Int 40:355-360. (Pubitemid 34131610)
46. Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG. 2009. Quetiapineaugments the effect of citalopram in non-refractory obsessive-compulsive disorder: A randomized, double-blind, placebocontrolled study of 76 patients. J Clin Psychiatry 70:1001-1008.
47. Zohar J, Zohar-Kadouch RC, Kindler S. 1992. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 43:210-218.
48. Zohar J, Insel TR. 1987. Obsessive-compulsive disorder: psycho-biological approaches to diagnosis, treatment, and patho-physiology, Biol Psychiatry 22:667-687. (Pubitemid 17101476)